Design, synthesis, and biological evaluation of new thieno[2,3-d] pyrimidine derivatives as targeted therapy for PI3K with molecular modelling study

References

• Siegel RL, Miller KD, Jemal A. Cancer facts & figures 2018, CA. Cancer J Clin 2018;68:7–30.
   PubMed Web of Science ®Google Scholar
• Avendaño López C, Menendez JC. General aspects of cancer chemotherapy. In: Medicinal chemistry of anticancer drugs. Amsterdam, The Netherlands: Elsevier; 2015;1–22.
   Google Scholar
• Ibrahim AS. Cancer: the growing monster in Egypt. J Cancer Prev Curr Res 2016;6:6–7.
   Google Scholar
• Moses C, Garcia-Bloj B, Harvey AR, Blancafort P. Hallmarks of cancer: the CRISPR generation. Eur J Cancer 2018;93:10–8.
   PubMed Web of Science ®Google Scholar
• Siddiqui IA, Sanna V, Ahmad N, et al. Resveratrol nanoformulation for cancer prevention and therapy. Ann NY Sci Acad 2015;1348:20–31.
   PubMed Web of Science ®Google Scholar
• Scheeff ED, Bourne PE. Structural evolution of the protein kinase – like superfamily. PLoS Comput Biol 2005;1:e49.
   PubMed Web of Science ®Google Scholar
• Ferguson FM, Gray NS. Kinase inhibitors: the road ahead. Nat Rev Drug Discov 2018;17:353–76.
   PubMed Web of Science ®Google Scholar
• Lipid Kinase-enzyme. Available from: http://www.sinobiological.com/lipid-kinase-enzyme.html (Last accessed 24 Dec 2018).
   Google Scholar
• Han MW, Ryu IS, Lee JC, et al. Phosphorylation of PI3K regulatory subunit p85 contributes to resistance against PI3K inhibitors in radioresistant head and neck cancer. Oral Oncol 2018;78:56–63.
   PubMed Web of Science ®Google Scholar
• Marone R, Cmiljanovic V, Giese B, Wymann MP. Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim Biophys Acta 2008;1784:159–85.
   PubMed Web of Science ®Google Scholar
• Workman P, Clarke PA, Raynaud FI, Van Montfort RLM. Drugging the PI3 Kinome: from chemical tools to drugs in the Clinic. Cancer Res. 2010;3:2146–58.
   Google Scholar
• Dey N, De P, Leyland-Jones B. PI3K-AKT-mTOR inhibitors in breast cancers: from tumor cell signaling to clinical trials. Pharmacol Ther 2017;175:91–106.
   PubMed Web of Science ®Google Scholar
• Kong DX, Yamori T. ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor identified using the JFCR39 drug discovery system. Acta Pharmacol Sin 2010;31:1189–97.
   PubMed Web of Science ®Google Scholar
• Bauer TM, Patel MR, Infante JR. Targeting PI3 kinase in cancer. Pharmacol Ther 2015;146:53–60.
   PubMed Web of Science ®Google Scholar
• McNamara CR, Degterev A. Small-molecule inhibitors of the PI3K signaling network. Future Med Chem 2011;3:549–65.
   PubMed Web of Science ®Google Scholar
• Elmenier FM, Lasheen DS, Abouzid KAM. Phosphatidylinositol 3 kinase (PI3K) inhibitors as new weapon to combat cancer. Euro J Med Chem 2019;183:111718.
   PubMed Web of Science ®Google Scholar
• Thorpe LM, Yuzugullu H, Zhao JJ. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer 2015;15:7–24.
   PubMed Web of Science ®Google Scholar
• Vadas O, Burke JE. Probing the dynamic regulation of peripheral membrane proteins using hydrogen deuterium exchange-MS (HDX-MS). Biochem Soc Trans 2015;43:773–86.
   PubMed Web of Science ®Google Scholar
• AliqopaTM (copanlisib) | Official Site for Healthcare Professionals. Available from: https://www.hcp.aliqopa-us.com/ (Last accessed 03 Oct 2019).
   Google Scholar
• FDA approves Novartis’ PI3K inhibitor for breast cancer. Available from: http://www.pharmtech.com›fda-approves-novartis-pi3k-inhibitor-breast-cancer (Last accessed 30 May 2019).
   Google Scholar
• Wei M, Zhang X, Wang X, et al. SAR study of 5-alkynyl substituted quinazolin-4(3H)-ones as phosphoinositide 3-kinase delta (PI3Kδ) inhibitors. Eur J Med Chem 2017;125:1156–71.
   PubMed Web of Science ®Google Scholar
• Göckeritz E, Kerwien S, Baumann M, et al. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells. Int J Cancer 2015;137:2234–42.
   PubMed Web of Science ®Google Scholar
• Balakrishnan K, Peluso M, Fu M, et al. The phosphoinositide-3-kinase (PI3K) -delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL. Leukemia 2015;29:1811–22.
   PubMed Web of Science ®Google Scholar
• PI3K Delta Gamma Inhibitor | Verastem Oncology. Available from: https://www.verastem.com/pipeline/duvelisib-pi3k-delta-pi3k-gamma-inhibitor/ (Last accessed 18 Jan 2019).
   Google Scholar
• COPIKTRA TM (duvelisib) | Patients | Official Website. Available from: https://www.copiktra.com/ (Last accessed 18 Jan 2019).
   Google Scholar
• Flinn IW, O’Brien S, Kahl B, et al. Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies. Blood 2018;131:877–87.
   PubMed Web of Science ®Google Scholar
• Miller MS, Thompson PE, Gabelli SB. Structural determinants of isoform selectivity in PIK inhibitors. Biomolecules 2019;9:82.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Zhang X, Chen Y, et al. Crystal structures of PI3Kα complexed with PI103 and Its derivatives: new directions for inhibitors design. ACS Med Chem Lett 2014;5:138–42.
   PubMed Web of Science ®Google Scholar
• Li J-J, Corey EJ. Name reactions in heterocyclic chemistry. Hoboken, NJ: Wiley; 2004:183–217.
   Google Scholar
• Al-Mousawi S, Moustafa MS, Elnagdi MH. Studies with enamines: functionally substituted enamines as aldehyde equivalents in Gewald reactions. Arkivoc 2007;2008:17–25.
   Google Scholar
• Bacon ER, Daum SJ. Synthesis of 7-ethyl-4,7-dihydro-4-oxo-2-(4-pyridinyl)thieno[2,3- b]pyridine-5-carboxylic acid. J Heterocycl Chem 1991;28:1953–5.
   Web of Science ®Google Scholar
• Puterova Z, Krutošíková A, Végh D. Gewald reaction: synthesis, properties and applications of substituted 2-aminothiophenes. Arkivoc 2010;2010:209–46.
   Google Scholar
• Gouda A, Berghot MA, Abd El-Ghani GE, Elattar KM. Chemistry of 2-aminothiophene-3-carboxamide and related compounds. Turk J Chem 2011;35:815–37.
   Web of Science ®Google Scholar
• Bogolubsky AV, Ryabukhin SV, Plaskon AS, et al. Dry HCl in parallel synthesis of fused pyrimidin-4-ones. J Comb Chem 2008;10:858–62.
   PubMed Web of Science ®Google Scholar
• Amawi H, Karthikeyan C, Pathak R, et al. Thienopyrimidine derivatives exert their anticancer efficacy via apoptosis induction, oxidative stress and mitotic catastrophe. Eur J Med Chem 2017;138:1053–65.
   PubMed Web of Science ®Google Scholar
• Ragheb, EAB. Synthesis of thieno-pyrimidine derivatives as cytotoxic agents [Master’s Thesis]. Cairo, Egypt: Cairo University; 2010.
   Google Scholar
• Abdel-Megid M, Elmahdy KM, Elkazak AM, et al. Chemistry of thienopyrimidines and their biological applications. J Pharm Appl Chem 2016;2:103–27.
   Google Scholar
• Kassab AE, Gedawy EM. Synthesis and anticancer activity of novel 2-pyridyl hexahyrocyclooctathieno[2,3-d]pyrimidine derivatives. Eur J Med Chem 2013;63:224–30.
   PubMed Web of Science ®Google Scholar
• Katritzky AR. Advances in heterocyclic chemistry. Amsterdam, The Netherlands: Elsevier Science; 1996:403.
   Google Scholar
• Kar RK, Suryadevara P, Roushan R, et al. Quantifying the structural requirements for designing newer flt3 inhibitors. Med Chem 2012;8:913–27.
   PubMed Web of Science ®Google Scholar
• Varvounis G, Giannopoulos T. Synthesis, chemistry, and biological properties of thienopyrimidines. Adv Heterocycl Chem 1996;66:193–283.
   Google Scholar
• Samala G, Devi PB, Saxena S, et al. Anti-tubercular activities of 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amine analogues endowed with high activity toward non-replicative Mycobacterium tuberculosis. Bioorg Med Chem 2016;24:5556–64.
   PubMed Web of Science ®Google Scholar
• Bassetto M, Leyssen P, Neyts J, et al. Computer-aided identification, synthesis and evaluation of substituted thienopyrimidines as novel inhibitors of HCV replication. Eur J Med Chem 2016;123:31–47.
   PubMed Web of Science ®Google Scholar
• Arnott EA, Chan LC, Cox BG, et al. POCl3 chlorination of 4-quinazolones. J Org Chem 2011;76:1653–61.
   PubMed Web of Science ®Google Scholar
• Leggio A, Belsito EL, De Luca G, et al. RSC advances one-pot synthesis of amides from carboxylic acids activated using thionyl chloride †. RSC Adv 2016;6:34468–75.
   Web of Science ®Google Scholar
• Suzuki T, Khan MNA, Sawada H, et al. Hidehiko Nakagawa, and Naoki Miyata, design, synthesis, and biological activity of a novel series of human sirtuin-2-selective inhibitors. J Med Chem 2012;55:5760–73.
   PubMed Web of Science ®Google Scholar
• Ono N. The nitro group in organic synthesis. Vol. 9. Hoboken, NJ: John Wiley & Sons; 2003:170–175.
   Google Scholar
• Kumar PS, Sunil J, Gurrala S, Bathini R. Antimicrobial screening of some novel Tetramethylene thiophene derivatives synthesized using various aryl acid chlorides Antimicrobial screening of some novel Tetramethylene thiophene derivatives synthesized using various aryl acid chlorides. J Pharm Res 2011;4:2–5.
   Google Scholar
• Sarangapani M, Sridhar D, Arjun M, Adharvana Chari M. Synthesis of some novel 2-substituted-N-aryl-benzoxazole-5-carboxamides using cobalt dipyridine dichloride as a catalyst. J Heterocycl Chem 2008;45:1187–90.
   Web of Science ®Google Scholar
• Lunagariya NA, Gohil VM, Kushwah V, et al. Design, synthesis and biological evaluation of 1,3,6-trisubstituted β-carboline derivatives for cytotoxic and anti-leishmanial potential. Bioorg Med Chem Lett 2015;26:789–794.
   PubMed Web of Science ®Google Scholar
• Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006;6:813–23.
   PubMed Web of Science ®Google Scholar
• She Q-B, Chandarlapaty S, Ye Q, et al. Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to akt signaling. PLoS One 2008;3:e3065.
   PubMed Web of Science ®Google Scholar
• Graupera M, Guillermet-Guibert J, Foukas LC, et al. Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. Nature 2008;453:662–6.
   PubMed Web of Science ®Google Scholar
• Schneck H, Blassl C, Meier-Stiegen F, et al. Analysing the mutational status of PIK3CA in circulating tumor cells from metastatic breast cancer patients. Mol Oncol 2013;7:976–86.
   PubMed Web of Science ®Google Scholar
• Vora SR, Juric D, Kim N, et al. CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. Cancer Cell 2014;26:136–49.
   PubMed Web of Science ®Google Scholar
• Chikh A, Ferro R, Abbott JJ, et al. Class II phosphoinositide 3-kinase C2β regulates a novel signaling pathway involved in breast cancer progression. Oncotarget 2016;7:18325–45.
   PubMedGoogle Scholar
• Ebi H, Costa C, Faber AC, et al. PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1. Proc Natl Acad Sci USA 2013;110:21124–9.
   PubMed Web of Science ®Google Scholar
• Adel M, Serya RAT, Lasheen DS, Abouzid KAM. Identification of new pyrrolo[2,3-d]pyrimidines as potent VEGFR-2 tyrosine kinase inhibitors: design, synthesis, biological evaluation and molecular modeling. Bioorg Chem 2018;81:612–29.
   PubMed Web of Science ®Google Scholar
• Cheeseright T, Mackey M, Rose S, Vinter A. Molecular field extrema as descriptors of biological activity: definition and validation. J Chem Inf Model 2006;46:665–76.,
   PubMed Web of Science ®Google Scholar
• Wu G, Robertson DH, Iii CLB, Vieth M. Detailed analysis of grid-based molecular docking: a case study of CDOCKER — a CHARMm-based MD docking algorithm. J Comput Chem 2003;24:1549–62.
   PubMed Web of Science ®Google Scholar
• Brooks BR, Brooks CL, Mackerell AD, et al. CHARMM: the biomolecular simulation program. J Comput Chem 2009;30:1545–614.
   PubMed Web of Science ®Google Scholar
• Dzhavakhishvili SG, Gorobets NY, Musatov VI, et al. Three possible products from the reactions of Gewald’s amide with aromatic aldehydes. J Heterocycl Chem 2008;45:573–7.
   Web of Science ®Google Scholar
• Li JJ. Schotten-Baumann reaction. In: Name reaction: a collection of details reaction mechanism. Berlin, Germany: Springer; 2003:362.
   Google Scholar